Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe
Mathison, Angela , Salmonson, Ann, Missfeldt, Mckenna, Bintz, Jennifer , Williams, Monique , Kossak, Sarah, Nair, Asha, Assuncao, Thiago M. de , Christensen, Trace , Buttar, Navtej , Lomberk, Gwen , De Assuncao, Thiago M, Huebert, Robert, Iovanna, Juan , Huebert, Robert C. , Lomberk, Gwen L , Mathison, Angela J

Mayo Clinic

Molecular Cancer Research | April 25, 2017 | Volume: 15 | Issue: 8 | Pages: 984-997

10.1158/1541-7786.mcr-17-0063 | PMID 28442587 Get It

Abstract The current integrative pathobiologic hypothesis states that pancreatic cancer (PDAC) develops and progresses in response to an interaction between known oncogenes and downstream epigenomic regulators. Congruently, this study tests a new combinatorial therapy based on the inhibition of the Aurora kinase A (AURKA) oncogene and one of its targets, the H3K9 methylation–based epigenetic pathway. This therapeutic combination is effective at inhibiting the in vitro growth of PDAC cells both, in monolayer culture systems, and in three-dimensional spheroids and organoids. The combination also reduces the growth of PDAC xenografts in vivo. Mechanistically, it was found that inhibiting methyltransferases of the H3K9 pathway in cells, which are arrested in G2–M after targeting AURKA, decreases H3K9 methylation at centromeres, induces mitotic aberrations, triggers an aberrant mitotic check point response, and ultimately leads to mitotic catastrophe. Combined, these data describe for the first time a hypothesis-driven design of an efficient combinatorial treatment that targets a dual oncogenic–epigenomic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe. Therefore, this new knowledge has significant mechanistic value as it relates to the development of new therapies as well as biomedical relevance. Implications: These results outline a model for the combined inhibition of a genetic-to-epigenetic pathway to inhibit cell growth and suggest an important and provocative consideration for harnessing the capacity of cell-cycle inhibitors to enhance the future use of epigenetic inhibitors. Mol Cancer Res; 15(8); 984–97. ©2017 AACR.
Recruitment of human light chain proteins by synthetic fibrils is dependent on disease state and may be used to predict amyloidogenic propensity
Martin, Emily B. , Williams, Angela, Wooliver, Craig, Heidel, R. Eric , Adams, Sarah, Dunlap, John R., Ramı́rez-Alvarado, Marina , Blancas‐Mejía, Luis M. , Kennel, Stephen J., Wall, Jonathan S. , Blancas-Mejia, Luis, Ramirez-Alvarado, Marina

Mayo Clinic

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 24-25

10.1080/13506129.2017.1295374 | PMID 28434355 Get It

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial
Gall, Émilie Cornec-Le , Blais, Jaime D., Irazabal, María V. , Devuyst, Olivier , Gansevoort, Ron T. , Perrone, R. D., Chapman, Arlene B., Czerwiec, Frank S., Ouyang, John , Heyer, Christina M., Senum, Sarah R. , Meur, Yannick Le , Torres, Vicente E. , Harris, Peter C. , Cornec-Le Gall, Emilie, Harris, Peter C , Torres, Vicente E , Senum, Sarah R , Irazabal, Maria V , Cornec-Le Gall, Emilie , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767

Mayo Clinic

Nephrology Dialysis Transplantation | April 20, 2017 | Volume: 33 | Issue: 4 | Pages: 645-652

10.1093/ndt/gfx188 | PMID 28992127 Get It

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Chintakuntlawar, Ashish V. , Rumilla, Kandelaria M., Jenkins, Sarah M. , Foote, Robert L. , Kasperbauer, Jan L. , Ryder, Mabel , Alsidawi, Samer , Hilger, Crystal, Bible, Keith C. , Smith, Carin Y. , Morris, John C., Chintakuntlawar, Ashish V , Ryder, Mabel

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 19, 2017 | Volume: 102 | Issue: 6 | Pages: 1943-1950

10.1210/jc.2016-3756 | PMID 28324060 Get It

External Arrhythmia Ablation Using Photon Beams
Deisher, A., Takami, Mitsuru , Kruse, Jon J. , Song, Limin, Anderson, Sarah , Cusma, Jack T., Parker, Kay D., Johnson, Susan B., Asirvatham, Samuel J. , Miller, Robert C. , Herman, Michael , Packer, Douglas L. , Lehmann, H. Immo , Deisher, Amanda J, Anderson, Sarah E, Herman, Michael G., Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 13, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circep.116.004304 | PMID 28408649 Get It

Background— This study sought to investigate external photon beam radiation for catheter-free ablation of the atrioventricular junction in intact pigs. Methods and Results— Ten pigs were randomized to either sham irradiation or irradiation of the atrioventricular junction (55, 50, 40, and 25 Gy). Animals underwent baseline electrophysiological evaluation, cardiac gated multi-row computed tomographic imaging for beam delivery planning, and intensity-modulated radiation therapy. Doses to the coronary arteries were optimized. Invasive follow-up was conducted ≤4 months after the irradiation. A mean volume of 2.5±0.5 mL was irradiated with target dose. The mean follow-up length after irradiation was 124.8±30.8 days. Out of 7 irradiated animals, complete atrioventricular block was achieved in 6 animals of all 4 dose groups (86%). Using the same targeting margins, ablation lesion size notably increased with the delivered dose because of volumetric effects of isodose lines around the target volume. The mean macroscopically calculated atrial lesion volume for all 4 dose groups was 3.8±1.1 mL, lesions extended anteriorly into the interventricular septum. No short-term side effects were observed. No damage was observed in the tissues of the esophagus, phrenic nerves, or trachea. However, histology revealed in-field beam effects outside of the target volume. Conclusions— Single-fraction doses as low as 25 Gy caused a lesion with interruption of cardiac impulse propagation using this respective target volume. With doses of ≤55 Gy, maximal point-doses to coronary arteries could be kept <7Gy, but target conformity of lesions was not fully achieved using this approach.
CAHPS Cancer Care Survey: Development, testing, and final content of a survey of patient experience with cancer care.
Evensen, Christian, Yost, Kathleen J. , Keller, San, Cowans, Tamika, Frentzel, Elizabeth , Jenkins, Sarah M. , Egginton, Jason S. , Arora, Neeraj, Garfinkel, Steven

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 35 | Issue: 8_suppl | Pages: 227-227

10.1200/jco.2017.35.8_suppl.227 Get It

227 Background: The objective of this work was to develop a reliable and valid survey measuring aspects of cancer care important to patients to be used in both inpatient and outpatient settings, and that allows comparisons of patient experiences across treatment centers and treatment modalities (medical oncology, radiation, surgery). Other objectives included testing various modes of data collection and developing a standardized sampling methodology based on ICD diagnosis and procedure codes. Methods: We conducted focus groups with patients who had received cancer treatment and with family members of cancer patients. We convened a panel of experts representing quality improvement, oncology, shared decision-making, patient safety, and patient advocacy to obtain feedback on the development of the survey. We interviewed stakeholder groups representing oncology associations to obtain feedback on focal provider, attribution and sampling. We then conducted a field test of the survey among six cancer centers around the country, conducted psychometric analyses, revised the survey, conducted a second field test among four community oncology practices in CA, re-analyzed the data, and finalized the survey. Results: Final survey content was determined using results of the formative research, psychometric analyses, and input from the CAHPS Consortium. The core survey includes 56 questions, 23 of which map to eight composites: Provider Communication, Enabling Patient Self-management, Team Available to Provide Information, Access to Care, Care Coordination, and Office Staff. Supplemental item sets include seven items assessing Shared Decision Making, four items measuring Keeping Patients Informed, and two additional Access to Care items. Mail-only, mail-telephone mixed-mode, and web-mail mixed-mode are recommended methods of data collection. The survey and all recruiting materials are available in English and Spanish. Conclusions: The CAHPS Cancer Care Survey is a rigorously developed, well-tested, reliable and valid survey of patient experiences with their cancer care. The survey and supporting materials are available free of charge on the CAHPS website (www.ahrq.gov/cahps).
Precancer Atlas to Drive Precision Prevention Trials
Spira, Avrum, Yurgelun, Matthew B., Alexandrov, Ludmil, Rao, Anjana, Bejar, Rafael, Polyak, Kornelia, Giannakis, Marios, Shilatifard, Ali, Finn, Olivera J., Dhodapkar, Madhav, Kay, Neil E., Braggio, Esteban, Vilar, Eduardo, Mazzilli, Sarah A., Rebbeck, Timothy R., Garber, Judy E., Velculescu, Victor E., Disis, Mary L., Wallace, Douglas C., Lippman, Scott M., Braggio, Esteban , Velculescu, Victor E. , Alexandrov, Ludmil B. , Spira, Avrum, Yurgelun, Matthew B., Alexandrov, Ludmil, Rao, Anjana, Bejar, Rafael, Polyak, Kornelia, Giannakis, Marios, Shilatifard, Ali, Finn, Olivera J., Dhodapkar, Madhav, Kay, Neil E., Braggio, Esteban, Vilar, Eduardo, Mazzilli, Sarah A., Rebbeck, Timothy R., Garber, Judy E., Velculescu, Victor E., Disis, Mary L., Wallace, Douglas C., Lippman, Scott M., Braggio, Esteban , Alexandrov, Ludmil B

Mayo Clinic

Cancer Research | April 3, 2017 | Volume: 77 | Issue: 7 | Pages: 1510-1541

10.1158/0008-5472.can-16-2346 | PMID 28373404 Get It

Abstract Cancer development is a complex process driven by inherited and acquired molecular and cellular alterations. Prevention is the holy grail of cancer elimination, but making this a reality will take a fundamental rethinking and deep understanding of premalignant biology. In this Perspective, we propose a national concerted effort to create a Precancer Atlas (PCA), integrating multi-omics and immunity – basic tenets of the neoplastic process. The biology of neoplasia caused by germline mutations has led to paradigm-changing precision prevention efforts, including: tumor testing for mismatch repair (MMR) deficiency in Lynch syndrome establishing a new paradigm, combinatorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imaging-based early detection research in high-germline risk for pancreatic neoplasia, elucidating early ontogeny in BRCA1-mutation carriers leading to an international breast cancer prevention trial, and insights into the intricate germline-somatic-immunity interaction landscape. Emerging genetic and pharmacologic (metformin) disruption of mitochondrial (mt) respiration increased autophagy to prevent cancer in a Li-Fraumeni mouse model (biology reproduced in clinical pilot) and revealed profound influences of subtle changes in mt DNA background variation on obesity, aging, and cancer risk. The elaborate communication between the immune system and neoplasia includes an increasingly complex cellular microenvironment and dynamic interactions between host genetics, environmental factors, and microbes in shaping the immune response. Cancer vaccines are in early murine and clinical precancer studies, building on the recent successes of immunotherapy and HPV vaccine immune prevention. Molecular monitoring in Barrett's esophagus to avoid overdiagnosis/treatment highlights an important PCA theme. Next generation sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potential (CHIP). Ultra-deep NGS reports over the past year have redefined the premalignant landscape remarkably identifying tiny clones in the blood of up to 95% of women in their 50s, suggesting that potentially premalignant clones are ubiquitous. Similar data from eyelid skin and peritoneal and uterine lavage fluid provide unprecedented opportunities to dissect the earliest phases of stem/progenitor clonal (and microenvironment) evolution/diversity with new single-cell and liquid biopsy technologies. Cancer mutational signatures reflect exogenous or endogenous processes imprinted over time in precursors. Accelerating the prevention of cancer will require a large-scale, longitudinal effort, leveraging diverse disciplines (from genetics, biochemistry, and immunology to mathematics, computational biology, and engineering), initiatives, technologies, and models in developing an integrated multi-omics and immunity PCA – an immense national resource to interrogate, target, and intercept events that drive oncogenesis. Cancer Res; 77(7); 1510–41. ©2017 AACR.
Satisfaction and Occupational Performance in Patients with Functional Movement Disorder
Dahlhauser, Sarah E, Theuer, Amanda, Hollman, John H.

Mayo Clinic

The Open Journal of Occupational Therapy | April 1, 2017 | Volume: 5 | Issue: 2 | Pages: No page available

10.15453/2168-6408.1287 Get It

Background: Behavioral Shaping Therapy (BeST) is a program that uses a multidisciplinary approach to treat patients diagnosed with functional movement disorder (FMD). While this diagnosis is classified as a psychological disorder by the Diagnostic and Statistical Manual of Mental Disorders, the BeST program focuses on treating the physical manifestations of FMD. Occupational therapists are an integral part of the multidisciplinary team, employing a variety of cognitive behavioral and motor reprogramming techniques to normalize movement patterns. Method: Patients 18 years of age or older with a confirmed diagnosis of FMD participated in this study. This retrospective chart review used the Canadian Occupation Performance Measure to examine the patients’ satisfaction and perceived change in task performance on discharge from the program. Results: Results from the dependent t-test indicated a positive outcome after participating in the BeST program, with a mean change in performance of 3.4 and a mean change in satisfaction of 4.7. Discussion: This study shows that occupational therapy can have a positive effect on patients diagnosed with FMD.
Intact blood pressure, but not sympathetic, responsiveness to sympathoexcitatory stimuli in a patient with unilateral carotid body resection
Larson, Kathryn F. , Limberg, Jacqueline K. , Baker, Sarah E. , Joyner, Michael J. , Curry, Timothy B. , Joyner, Michael J , Baker, Sarah E

Mayo Clinic

Physiological Reports | March 31, 2017 | Volume: 5 | Issue: 7 | Pages: e13212

10.14814/phy2.13212 | PMID 28364029 Get It

Whole exome sequencing of a patient with suspected mitochondrial myopathy reveals novel compound heterozygous variants in RYR 1
Blackburn, Patrick R. , Selcen, Duygu , Gass, Jennifer , Jackson, Jessica L. , Macklin, Sarah , Cousin, Margot A. , Boczek, Nicole J. , Klee, Eric W. , Dimberg, Elliot L., Kennelly, Kathleen D., Gass, Jennifer M , Atwal, Paldeep S , Cousin, Margot A

Mayo Clinic

Molecular Genetics & Genomic Medicine | March 31, 2017 | Volume: 5 | Issue: 3 | Pages: 295-302

10.1002/mgg3.280 | PMID 28547000 Get It

Abstract Background Pathogenic variants in ryanodine receptor 1 ( RYR 1, MIM # 180901) are the cause of congenital myopathy with fiber‐type disproportion, malignant hyperthermia susceptibility type 1, central core disease of muscle, multiminicore disease and other congenital myopathies. Methods We present a patient with global developmental delay, hypotonia, myopathy, joint hypermobility, and multiple other systemic complaints that were noted early in life. Later she was found to have multiple bone deformities involving her spine, with severe scoliosis that was corrected surgically. She was also diagnosed with ophthalmoplegia, chronic hypercapnic respiratory failure, and hypertension. At 22 years of age she presented to the genetics clinic with a diagnosis of mitochondrial myopathy and underwent whole exome sequencing ( WES ). Results Whole exome sequencing revealed two novel compound heterozygous variants in RYR 1 (c.7060_7062del, p.Val2354del and c.4485_4500del, p.Tyr1495X). Conclusion Review of her clinical, pathologic, and genetic findings pointed to a diagnosis of a congenital myopathy with fiber‐type disproportion.